[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-380533-105":59,"doc-detail-380533-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","comparison-of-second-line-treatments-in-metastatic-renal-cell-carcinoma-patients-a-single-center-experience","Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma Patients - A Single-Center Experience","","Retrospective observational analysis of 81 patients with metastatic renal cell carcinoma receiving axitinib (n=29) or nivolumab (n=52) as second-line treatment at a single oncology outpatient clinic. Median follow-up was 18.5 months. Median second-line duration was 14 months with axitinib and 13.5 months with nivolumab. In predefined subgroups, nivolumab showed statistically better PFS and OS versus axitinib in multiple risk and timing categories, including specific male and metastatic timing patterns. NCCN supports both agents, while further prospective trials with larger cohorts are needed.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/comparison-of-second-line-treatments-in-metastatic-renal-cell-carcinoma-patients-a-single-center-experience/380533/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/comparison-of-second-line-treatments-in-metastatic-renal-cell-carcinoma-patients-a-single-center-experience/380533.png","ImageObject",300,407,{"name":92,"@type":93},"eBook King","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What treatments were compared in this study for second-line metastatic renal cell carcinoma?","Question",{"text":113,"@type":114},"The study compared axitinib versus nivolumab as second-line treatments in patients with metastatic renal cell carcinoma.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was the study designed and which patients were included?",{"text":118,"@type":114},"The study was a retrospective analysis. Patients receiving axitinib or nivolumab as second-line treatment at the Istanbul University Oncology Institute outpatient clinic were included, while those under 18, receiving other drugs, or lacking metastatic disease were excluded.",{"name":120,"@type":111,"acceptedAnswer":121},"What were the main efficacy findings regarding PFS and OS?",{"text":122,"@type":114},"Nivolumab demonstrated statistically better PFS and OS outcomes than axitinib across several patient subgroups, including men, certain risk categories, and specific metastatic timing patterns.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},380533,1790811938,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":46},962088006270,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","®  \n Observational Study   \nComparison of second-line treatments in metastatic renal cell carcinoma patients A single-center experience  \nMetin Pehlivan, MDa,*  , Nail Paksoy, MDb , Esra Aydın, MDb , Mert Basaran, Profb , Meltem Ekenel, Profb  \n\n| Abstract\u003Cbr>Renal cell carcinoma is the 10th most common type of cancer, accounting for 3.7% of all cancers. Our study examines patients with metastatic renal cell carcinoma who received Axitinib or Nivolumab as second-line treatment. This study was designed as a retrospective analysis. Patients who received Axitinib or Nivolumab as second-line treatment for metastatic renal cell carcinoma at the Istanbul University Oncology Institute Medical Oncology outpatient clinic were included in the study. A total of 81 patients were included in the study, with a median follow-up period of 18.5 months (2–260 months) . Of these patients, 29 (35 .8%) received Axitinib as second-line treatment, while 52 (64 .2%) received Nivolumab. The median duration of second-line treatment was 14 months (6-52) for Axitinib and 13.5 months (3–77) for Nivolumab. In our study, Nivolumab was found to have statistically better PFS and OS outcomes than Axitinib in male patients, patients diagnosed with metastatic disease, those with a favorable or intermediate International Metastatic Renal Cell Carcinoma Database Consortium risk score, patients diagnosed with metastatic disease or who developed metastasis within 12 months of diagnosis, those who developed metastasis ≥ 24 months after diagnosis, and patients with metastasis in a single organ. Both drugs are recommended as monotherapy for second-line and later treatments in the current NCCN guidelines for kidney cancers. Although there is no study in the literature showing that axitinibis more effective than nivolumab, nivolumab was found to be much more effective than axitinib in our study. Prospective studies with higher number of patients are needed on this subject. |\n| --- |\n| Abbreviations: IMDC = International Metastatic Renal Cell Carcinoma Database Consortium, RCC = renal cell carcinoma. |\n| Keywords: axitinib, mortality, nivolumab, renal cell carcinoma, survival |\n\n1. Introduction  \nRenal cell carcinoma (RCC) is the 10th most common type of cancer, accounting for 3.7% of all cancers. [1] RCC is more prevalent in developed countries, particularly in Western nations. Despite the increased utilization of imaging techniques, 17% of patients are diagnosed with distant metastasis. [2] Advanced age, obesity, male gender, and hypertension are the main risk factors. In 3% of cases, RCC occurs as a result of genetic syndromes such as Von Hippel-Lindau, Birt–Hogg–Dubé syndrome, among others. [3] Clear cell carcinoma (70–90%), papillary RCC (10–15%), and chromophobe (3–5%) are the most common histological subtypes. [4] Multikinase inhibitors and immune checkpoint inhibitors are used in the treatment of metastatic RCC. [1] Our study examines patients with metastatic RCC who received Axitinib or Nivolumab as second-line treatment.  \nThe authors have no funding and conflicts of interest to disclose. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.  \na Zonguldak Ataturk State Hospital Department of Medical Oncology, Zonguldak, Istanbul, Turkey, b İstanbul University Institute of Oncology, Zonguldak, Istanbul, Turkey.  \n* Correspondence: Metin Pehlivan, Zonguldak Ataturk State Hospital  \nDepartment of Medical Oncology, Zonguldak 67100, Istanbul, Turkey (e-mail: [metinpehlivan35@gmail.com](metinpehlivan35@gmail.com)).  \n2. Material and methods  \n2.1. Study design and patient characteristics  \nThis study was designed as a retrospective analysis. Patients who received Axitinib or Nivolumab as second-line treatment for metastatic renal cell carcinoma at the Istanbul University Oncology Institute Medical Oncology outpatient clinic were included in the study. Patients under the age of 18, thos","cbCaifzLzIlJMoZy","https://ap.wps.com/l/cbCaifzLzIlJMoZy","pdf",910658,"English","# Introduction\n# Material and methods\n## Study design and patient characteristics\n## Clinical parameters examined","[{\"question\":\"What treatments were compared in this study for second-line metastatic renal cell carcinoma?\",\"answer\":\"The study compared axitinib versus nivolumab as second-line treatments in patients with metastatic renal cell carcinoma.\"},{\"question\":\"How was the study designed and which patients were included?\",\"answer\":\"The study was a retrospective analysis. Patients receiving axitinib or nivolumab as second-line treatment at the Istanbul University Oncology Institute outpatient clinic were included, while those under 18, receiving other drugs, or lacking metastatic disease were excluded.\"},{\"question\":\"What were the main efficacy findings regarding PFS and OS?\",\"answer\":\"Nivolumab demonstrated statistically better PFS and OS outcomes than axitinib across several patient subgroups, including men, certain risk categories, and specific metastatic timing patterns.\"}]","Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma Patients - A Single-Center Experience | PDF",1790240568]